a1880p
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca
to deliver $80bn revenue by 2030
21 May 2024
AstraZeneca sets ambition to deliver $80 billion Total Revenue by
2030 and
sustained growth post 2030
Launch of 20 new medicines expected by 2030
Significant growth from existing oncology,
biopharmaceuticals
and rare disease portfolios
Investing in disruptive innovation that will shape the future of
medicine and
drive long-term growth
Decoupling carbon emissions from revenue growth
Today AstraZeneca revealed its bold ambition to deliver $80 billion
in Total Revenue by 2030, up from $45.8 billion in 2023. This will
be achieved through significant growth in its existing oncology,
biopharmaceuticals and rare disease portfolio, and by launching an
expected 20 new medicines before the end of the decade. To drive
sustained growth beyond 2030, the Company will continue investing
in transformative new technologies and platforms that will shape
the future of medicine.
AstraZeneca will maintain its strategic commitment to R&D while
focusing on productivity throughout the Company, driving operating
leverage and enabling the delivery of its ambition for a mid-30s
percentage Core operating margin by 2026. Beyond 2026, Core
operating margin will be influenced by portfolio evolution and the
company will target at least the mid-30s percentage
range.
Pascal Soriot, Chief Executive Officer, AstraZeneca said: "Today
AstraZeneca announces a new era of growth. In
2023 we delivered the ambitious $45 billion revenue goal set a
decade ago. With the exciting growth of our innovative pipeline,
which has the potential to transform millions of lives, we are now
aiming for $80 billion by 2030.
We are planning to launch 20 new medicines by 2030, many with the
potential to generate more than $5 billion in peak year
revenues. The breadth of our portfolio together with continued
investment in innovation supports sustained growth well past the
end of the decade."
As AstraZeneca continues to grow across all therapy areas, it will
continue to decouple its carbon emissions from its increase in
revenue. The Company has already reduced its greenhouse gas
emissions (Scopes 1 and 2) by 68% from its 2015 baseline while
growing Total Revenue by 85% over the same period. By 2026 the
Company will be carbon zero for Scope 1 and 2 emissions and by 2030
halve its Scope 3 emissions, on the way to science-based net zero
by 2045 at the latest.
Notes:
A webcast of the Investor Day event will begin today, 21 May 2024,
at 10:00 UK time. Details can be found at www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html
Basis of AstraZeneca's ambitions, forecasts and
targets
AstraZeneca's ambitions, forecasts and targets in this announcement
(the "Financial Ambition Statements") are derived from
AstraZeneca's most recent risk-adjusted mid- and long-term plans,
adjusted for developments in the business since those plans were
finalised. The
Financial Ambition Statements are based on management's
risk-adjusted projections for individual medicines and individual
clinical trials. Estimates for these probabilities are based on
industry-wide data for relevant clinical trials in the
pharmaceutical industry at a similar stage of development adjusted
for management's view on the risk profile of the specific asset.
The peak year revenue (PYR) potential for individual medicines
referred to in this announcement are the maximum estimated Total
Revenue to be recognised by AstraZeneca in a single calendar year,
during the lifecycle of the medicine, and are based on management's
latest non-risk-adjusted forecast estimates. Estimates are based on
customary forecasting methodologies used in the pharmaceutical
industry. Peak year revenue may occur in different years
for each NME depending on trial outcomes, approval label,
competition, launch dates and exclusivity periods, amongst other
variables. The peak year revenue figures are derived from net sales
at nominal values and are not risk-adjusted or time-value
discounted. The development of pharmaceutical products has
inherent risks given scientific experimentation and there are a
range of possible outcomes in clinical results, safety, efficacy
and product labelling. Clinical results may not achieve the desired
product profile and competitive environment, pricing and
reimbursement may have material impact on commercial revenue
forecasts. By their nature, forecasts are based on a multiplicity
of assumptions and actual performance in future years may vary,
significantly and materially, from these
assumptions. The
Financial Ambition Statements in this announcement are based on Q1
2024 exchange rates; AstraZeneca undertakes no obligation to update
those statements based on future currency
movements.
Attention is drawn to the notice set out under the heading Forward
Looking Statements below.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Forward Looking Statements
In order, among other things, to utilise the 'safe harbour'
provisions of the US Private Securities Litigation Reform Act of
1995, AstraZeneca (hereafter 'the Group') provides the following
cautionary statement:
This document contains certain forward-looking statements with
respect to the operations, performance and financial condition of
the Group, including, among other things, statements about expected
or targeted revenues, margins, earnings per share or other
financial or other measures (including the Financial Ambition
Statements described in this announcement). Although the Group
believes its expectations and targets are based on reasonable
assumptions and has used customary forecasting methodologies used
in the pharmaceutical industry and risk-adjusted projections for
individual medicines (which take into account the probability of
success of individual clinical trials, based on industry-wide data
for relevant clinical trials at a similar stage of development),
any forward-looking statements, by their very nature, involve risks
and uncertainties and may be influenced by factors that could cause
actual outcomes and results to be materially different from those
predicted. The forward-looking statements reflect knowledge and
information available at the date of preparation of this document
and the Group undertakes no obligation to update these
forward-looking statements. The Group identifies the
forward-looking statements by using the words 'anticipates',
'believes', 'expects', 'intends' and similar expressions in such
statements. Important factors that could cause actual results to
differ materially from those contained in forward-looking
statements, certain of which are beyond the Group's control,
include, among other things:
-
The risk of failure or delay in delivery of pipeline or launch of
new medicines;
-
the risk of failure to meet regulatory or ethical requirements for
medicine development or approval;
-
the risk of failures or delays in the quality or execution of the
Group's commercial strategies;
-
the risk of pricing, affordability, access and competitive
pressures;
-
the risk of failure to maintain supply of compliant, quality
medicines;
-
the risk of illegal trade in the Group's medicines;
-
the impact of reliance on third-party goods and
services;
-
the risk of failure in information technology or
cybersecurity;
-
the risk of failure of critical processes;
-
the risk of failure to collect and manage data in line with legal
and regulatory requirements and strategic objectives;
-
the risk of failure to attract, develop, engage and retain a
diverse, talented and capable workforce;
-
the risk of failure to meet regulatory or ethical expectations on
environmental impact, including climate change;
-
the risk of the safety and efficacy of marketed medicines being
questioned;
-
the risk of adverse outcome of litigation and/or governmental
investigations;
-
intellectual property-related risks to the Group's
products;
-
the risk of failure to achieve strategic plans or meet targets or
expectations;
-
the risk of failure in financial control or the occurrence of
fraud;
-
the risk of unexpected deterioration in the Group's financial
position;
-
the impact that global and/or geopolitical events may have, or
continue to have, on these risks, on the Group's ability to
continue to mitigate these risks, and on the Group's operations,
financial results or financial condition.
There can be no guarantees that the conditions to the closing of
the proposed transaction with Fusion will be satisfied on the
expected timetable, or at all, or that "FPI-2265" (Ac225-PSMA
I&T) or any combination product will receive the necessary
regulatory approvals or prove to be commercially successful if
approved. There can be no guarantees that the conditions to the
closing of the proposed transaction with Amolyt Pharma will be
satisfied on the expected timetable, or at all, or that
eneboparatide ("AZP-3601") will receive the necessary regulatory
approvals or prove to be commercially successful if
approved.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
21 May 2024
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|